论文部分内容阅读
目的 评价熊去氧胆酸（忧思弗）治疗慢性肝病尤其是慢性肝病伴肝内胆汁淤积的疗效及安全性。方法７５例慢性肝病患者日服优思弗胶囊，每次２５０ｍｇ，每日３次。结果 治疗前后患者临床症状除齿龈出血（Ｐ＝０．０８２３）、鼻出血（Ｐ＝０．１１０１）改善不明显外，其余症状均有明显改善（Ｐ＝０．０００１）。肝功能检测指标治疗前后均有显著改善（Ｐ均分别＜０．０５），并且随着疗程的延长，各项肝功能指标的改善率１２周均明显优于８周。根据疗效判断标准，在其８周时显效率为４２．６％，有效率为２６．５％，总有效率为６９．１％。１２周时显效率为４９．２％，有效率为３１．１％，总有效率为８０．３％，１２周的疗效优于８周。不良反应发生率为１０．６２％。结论优思弗用于治疗慢性肝病尤其是慢性肝病伴肝内胆汁淤积是安全和有效的。
Objective To evaluate the efficacy and safety of ursodeoxycholic acid (Zofisuofu) in the treatment of chronic liver disease, especially chronic liver disease with intrahepatic cholestasis. Methods Seventy-five patients with chronic liver disease were treated with Euphorbia capsules, each 250mg three times a day. Results Before and after treatment, the clinical symptoms except gingival bleeding (P = 0.0823) and epistaxis (P = 0.1101) were not significantly improved, the other symptoms were significantly improved (P = 0.0001). The indexes of liver function tests were significantly improved before and after treatment (all P <0.05, respectively), and with the prolongation of treatment, the improvement rate of each liver function index was significantly better than 8 weeks in 12 weeks. According to the criteria of curative effect, the effective rate was 42.6% at 8 weeks, the effective rate was 26.5% and the total effective rate was 69.1%. At 12 weeks, the effective rate was 49.2%, the effective rate was 31.1% and the total effective rate was 80.3%. The efficacy of 12 weeks was better than 8 weeks. The incidence of adverse reactions was 10.62%. Conclusion Use of Usulfan for the treatment of chronic liver disease, especially chronic liver disease with intrahepatic cholestasis is safe and effective.